EXSCIENTIA, a Dundee-based biotechnology firm, has entered into a collaboration with pharma-giant GlaxoSmithKline to use artificial intelligence (AI) to speed up drug discovery.
The contract could be worth as much as £33 million to Exscientia, in addition to research funding.
Edinburgh-based Frontier IP, which specialises in the commercialisation of intellectual property, and has a holding in Exscientia, saw its shares jump 11 per cent on the announcement.
The collaboration will see Exscientia combine its AI-enabled platform with GSK’s expertise in the field of drug discovery, to identify novel and selective small molecules for up to ten disease-related targets.
This deal follows a similar collaboration project with French pharma-giant Sanofi.
Exscientia’s technology uses artificial intelligence to analyse enormous amounts of data on drugs, using what it learns from this analysis to design millions of project-specific compounds which are pre-assessed for a number of criteria. Data is refined over a number of test-cycles, enabling the business to generate candidate drugs in a quarter of the time taken by traditional approaches.
Exscientia will receive research payments from GSK to undertake new discovery programmes with nominated targets, with the goal of delivering pre-clinical candidates. Should all ten projects advance, Exscientia will receive the full £33m.
Andrew Hopkins, the company’s chief executive: “The alliance provides further validation of our AI-driven platform and its potential to accelerate the discovery of novel, high-quality drug candidates.”
John Baldoni, senior vice president, platform science and technology at GSK, said: “We anticipate that Exscientia’s approach will accelerate the discovery of new molecules against high value GSK targets with speed and confidence.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here